Sodium 2-amino-4-nitro-6-sulfophenolate | 74525-32-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: Sodium 2-amino-4-nitro-6-sulfophenolate
• 英文别名: sodium;2-amino-4-nitro-6-sulfophenolate
• CAS: 74525-32-9
• 化学式: C₆H₅N₂O₆S*Na
• 分子量: 256.171
• InChiKey: YOXRRZORGVMZEE-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -3.21
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  158
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Sodium 2-amino-4-nitro-6-sulfophenolate 生成 2-氨基-4-硝基苯酚-6-磺酸
  参考文献：
  名称：

  NIKIFOROV, P. A.;DANILOV, S. D.;YANDUSHKINA, T. G.;KLUBOV, A. YA.;BELOGLA+

  摘要：

  DOI：
• 作为产物：
  描述：

  calcium;3-amino-2-hydroxy-5-nitrobenzenesulfonate 生成 Sodium 2-amino-4-nitro-6-sulfophenolate
  参考文献：
  名称：

  NIKIFOROV, P. A.;DANILOV, S. D.;YANDUSHKINA, T. G.;KLUBOV, A. YA.;BELOGLA+

  摘要：

  DOI：

文献信息

• 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma
  作者：Anisha Viswanathan、Dinesh Kute、Aliyu Musa、Saravanan Konda Mani、Vili Sipilä、Frank Emmert-Streib、Fedor I. Zubkov、Atash V. Gurbanov、Olli Yli-Harja、Meenakshisundaram Kandhavelu

  DOI：10.1016/j.ejmech.2019.01.021

  日期：2019.3

  Nerve growth factor receptor (NGFR), a member of kinase protein, is emerging as an important target for Glioblastoma (GBM) treatment. Overexpression of NGFR is observed in many metastatic cancers including GBM, promoting tumor migration and invasion. Hydrazones have been reported to effectively interact with receptor tyrosine kinases (RTKs). We report herein the synthesis of 23 arylhydrazones of active methylene compounds (AHAMCs) compounds and their anti-proliferative activity against GBM cell lines, LN229 and U87. Compound 8234, 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile, was identified as the most active anti-neoplastic compound, with the IC50 value ranging 87 mu M - 107 mu M Molecular docking simulations of the synthesized compounds into the active site of tyrosine receptor kinase A (TrkA), demonstrated a strong binding affinity with 8234 and concurs well with the obtained biological results. 8234 was found to be a negative regulator of PI3K/Akt/mTOR pathway and an enhancer of p53 expression. In addition, 8234 treated GBM cells exhibited the downregulation of cyclins, cyclin-dependent kinases and other key molecules involved in cell cycle such as CCNE, E2F, CCND, CDK6, indicating that 8234 induces cell cycle arrest at G1/S. R234 also exerted its apoptotic effects independent of caspase3/7 activity, in both cell lines. In U87 cells, 8234 induced oxidative effects whereas LN229 cells annulled oxidative stress. The study thus concludes that 8234, being a negative modulator of RTKs and cell cycle inhibitor, may represent a novel class of anti-GBM drugs. (C) 2019 Elsevier Masson SAS. All rights reserved.
• NIKIFOROV, P. A.;DANILOV, S. D.;YANDUSHKINA, T. G.;KLUBOV, A. YA.;BELOGLA+
  作者：NIKIFOROV, P. A.、DANILOV, S. D.、YANDUSHKINA, T. G.、KLUBOV, A. YA.、BELOGLA+

  DOI：——

  日期：——